JP7813222B2 - 高濃度抗ｃ５製剤 - Google Patents

高濃度抗ｃ５製剤

Info

Publication number
JP7813222B2
JP7813222B2 JP2022509593A JP2022509593A JP7813222B2 JP 7813222 B2 JP7813222 B2 JP 7813222B2 JP 2022509593 A JP2022509593 A JP 2022509593A JP 2022509593 A JP2022509593 A JP 2022509593A JP 7813222 B2 JP7813222 B2 JP 7813222B2
Authority
JP
Japan
Prior art keywords
formulation
pharmaceutical
pharmaceutical formulation
intravenous
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544589A (ja
JP2022544589A5 (enExample
Inventor
マリー・クレッペ
マヤンク・パテル
シャオリン・タン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72560889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7813222(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022544589A publication Critical patent/JP2022544589A/ja
Publication of JP2022544589A5 publication Critical patent/JP2022544589A5/ja
Priority to JP2025151837A priority Critical patent/JP2026003133A/ja
Application granted granted Critical
Publication of JP7813222B2 publication Critical patent/JP7813222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022509593A 2019-08-16 2020-08-14 高濃度抗ｃ５製剤 Active JP7813222B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025151837A JP2026003133A (ja) 2019-08-16 2025-09-12 高濃度抗ｃ５製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888086P 2019-08-16 2019-08-16
US62/888,086 2019-08-16
PCT/US2020/046314 WO2021034639A1 (en) 2019-08-16 2020-08-14 High concentration anti-c5 formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025151837A Division JP2026003133A (ja) 2019-08-16 2025-09-12 高濃度抗ｃ５製剤

Publications (3)

Publication Number Publication Date
JP2022544589A JP2022544589A (ja) 2022-10-19
JP2022544589A5 JP2022544589A5 (enExample) 2023-08-15
JP7813222B2 true JP7813222B2 (ja) 2026-02-12

Family

ID=72560889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509593A Active JP7813222B2 (ja) 2019-08-16 2020-08-14 高濃度抗ｃ５製剤
JP2025151837A Pending JP2026003133A (ja) 2019-08-16 2025-09-12 高濃度抗ｃ５製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025151837A Pending JP2026003133A (ja) 2019-08-16 2025-09-12 高濃度抗ｃ５製剤

Country Status (15)

Country Link
US (1) US20210046182A1 (enExample)
EP (1) EP4013784A1 (enExample)
JP (2) JP7813222B2 (enExample)
KR (1) KR20220047826A (enExample)
CN (1) CN116782876A (enExample)
AU (1) AU2020334880A1 (enExample)
BR (1) BR112022002831A2 (enExample)
CA (1) CA3145621A1 (enExample)
CL (1) CL2022000340A1 (enExample)
CO (1) CO2022001097A2 (enExample)
IL (1) IL290034A (enExample)
JO (1) JOP20220030A1 (enExample)
MX (1) MX2022001896A (enExample)
PH (1) PH12022550167A1 (enExample)
WO (1) WO2021034639A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970974T (pt) 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
AR130041A1 (es) * 2022-07-27 2024-10-30 Cephalon Llc Formulaciones de anticuerpos anti-tl1a
CN119894931A (zh) * 2022-07-27 2025-04-25 赛福伦有限责任公司 用于治疗溃疡性结肠炎和克罗恩病的抗tl1a抗体
JP2025536552A (ja) * 2022-10-28 2025-11-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗Ｃ５抗体／Ｃ５ ｉＲＮＡ合剤および併用療法
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
CN118460651B (zh) * 2024-07-10 2025-03-18 凯莱英医药集团（天津）股份有限公司 制备Cemdisiran的方法
CN119454939A (zh) * 2024-11-28 2025-02-18 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液及其制备方法
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515742A (ja) 2007-01-09 2010-05-13 ワイス エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
JP2012519706A (ja) 2009-03-06 2012-08-30 ジェネンテック， インコーポレイテッド 抗体製剤
JP2017105754A (ja) 2015-10-01 2017-06-15 ファイザー・インク 低粘度抗体組成物
WO2019023564A1 (en) 2017-07-27 2019-01-31 Alexion Pharmaceutical, Inc. ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION
WO2019084438A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC AND UREMIC SYNDROME (AHUS)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
CA2489174C (en) 2002-07-10 2013-02-05 Thomas Tuschl Rna-interference by single-stranded rna molecules
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
PT2970974T (pt) 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201691481A1 (ru) 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
CN109328197A (zh) 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP7275027B2 (ja) * 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
AU2018383751B2 (en) * 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515742A (ja) 2007-01-09 2010-05-13 ワイス エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
JP2012519706A (ja) 2009-03-06 2012-08-30 ジェネンテック， インコーポレイテッド 抗体製剤
JP2017105754A (ja) 2015-10-01 2017-06-15 ファイザー・インク 低粘度抗体組成物
WO2019023564A1 (en) 2017-07-27 2019-01-31 Alexion Pharmaceutical, Inc. ANTI-C5 ANTIBODY FORMULATIONS WITH HIGH CONCENTRATION
WO2019084438A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC AND UREMIC SYNDROME (AHUS)

Also Published As

Publication number Publication date
CA3145621A1 (en) 2021-02-25
US20210046182A1 (en) 2021-02-18
AU2020334880A1 (en) 2022-03-24
BR112022002831A2 (pt) 2022-06-28
WO2021034639A4 (en) 2021-04-15
CN116782876A (zh) 2023-09-19
CO2022001097A2 (es) 2022-03-08
JOP20220030A1 (ar) 2023-01-30
JP2022544589A (ja) 2022-10-19
EP4013784A1 (en) 2022-06-22
JP2026003133A (ja) 2026-01-09
PH12022550167A1 (en) 2023-05-08
WO2021034639A1 (en) 2021-02-25
CL2022000340A1 (es) 2022-10-07
MX2022001896A (es) 2022-06-02
IL290034A (en) 2022-03-01
KR20220047826A (ko) 2022-04-19

Similar Documents

Publication Publication Date Title
JP2026003133A (ja) 高濃度抗ｃ５製剤
JP7197623B2 (ja) 高度に濃縮された低粘度のｍａｓｐ－２阻害抗体製剤、キット、および方法
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
US20240247078A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods of treating subjects suffering from atypical hemolytic syndrome
JP2025521565A (ja) 補体が媒介する疾患を処置するための方法
US20240175027A1 (en) Anti-c5 antibody/c5 irna co-formulations and combination therapies
JP2025519600A (ja) 抗ｉｇｆ－１ｒ抗体組成物
HK40117196A (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
HK40075201B (en) Stable aqueous anti-tfpi antibody formulation
OA19221A (en) Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits, and methods
HK40009867B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
HK40009867A (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20220324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230804

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260130

R150 Certificate of patent or registration of utility model

Ref document number: 7813222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150